Position Trader

Swing Trading at the next level up

August 21, 2026

General Investing, Top Stock

Oscar Heath (OSCR) – Top Quant Stock of the Week – Shallow Dive

What does the company do?
Why Some Investors Are Bullish
What Bears Are Worried About
Why the Quants like this stock
My View

What does the company do?

Oscar Health, Inc. is a U.S.-based healthcare technology company that provides health plans for individuals, families, employees, and small businesses. It also offers the +Oscar healthcare platform, Campaign Builder for provider and payer engagement, reinsurance products, brokerage services, and an enrollment platform that helps consumers and brokers shop for and enroll in medical and supplemental health plans. Founded in 2012 and headquartered in New York City, the company was formerly known as Mulberry Health Inc. and adopted the Oscar Health name in January 2021.

Why Some Investors Are Bullish

Excellent Q2 results — Revenue reached $4.88 billion, up 70% year over year, while net income jumped to $361.8 million, or $1.10 per diluted share, from a $228.4 million loss a year earlier. Adjusted EBITDA reached $415.3 million, compared with a $199.4 million loss in Q2 2025.
Major margin improvement — The medical loss ratio improved to 79.2% from 91.1%, while the SG&A ratio fell to 14.2% from 18.7%. However, part of the MLR improvement came from $164 million of favorable prior-period reserve development, so investors shouldn’t assume all of the improvement is purely structural.
Raised 2026 guidance — Oscar increased its full-year earnings-from-operations outlook to $500–$700 million, up from its previous $250–$450 million range, while maintaining revenue guidance of $18.7–$19.0 billion. It also lowered its projected full-year MLR range to 81.5%–82.5%.
Strong membership growth — Effectuated membership reached approximately 2.96 million at June 30, compared with about 2.03 million a year earlier, an increase of roughly 46%. Oscar’s growth is being driven primarily by its Individual and Small Group offerings, although the company no longer offers small-group plans effective December 2024.
Technology remains an important differentiator — Oscar continues to position its technology platform and AI capabilities as important tools for improving member engagement, healthcare navigation and operating efficiency. The company’s broader strategy is built around combining health insurance with a technology-driven consumer experience.

What Bears Are Worried About

The stock’s reaction shows expectations are high — Despite the strong Q2 numbers and higher guidance, the market reaction was negative. That suggests investors may be looking beyond the current quarter and focusing on whether Oscar can sustain its unusually strong margins and profitability.
Medical-cost and membership risks remain — Oscar’s results remain highly sensitive to medical costs, risk adjustment and membership trends. A deterioration in medical claims or changes in the ACA marketplace could put pressure on margins and earnings.
Some of the margin improvement may not be repeatable — The Q2 MLR benefited from $164 million of favorable prior-period reserve development, meaning investors should be cautious about extrapolating the quarter’s 79.2% MLR indefinitely. Oscar’s full-year guidance still assumes an MLR of 81.5%–82.5%, indicating management expects some normalization.

Why the Quants like this stock

Price / Sales (FWD) A+ 0.53
Revenue Growth (FWD) A+ 30.28%
Operating Cash Flow Growth (YoY) A+ 257.99%
ROE Growth (FWD) A+ 117.65%
Return on Common Equity (TTM) A+ 34.31%
3M Price Performance A+ 31.73%
FY1 Up Revisions (last 90 days) 7 Up and 0 Down

My View

I like Oscar’s improving profitability, rapid membership growth and technology-driven business model. But after such a dramatic improvement in earnings, I would want to see how much of the margin expansion is sustainable before getting too aggressive—the next few quarters should tell us whether Oscar has truly turned a corner or simply benefited from unusually favorable conditions.

All content on this site is for informational purposes only and does not constitute financial advice. Consult relevant financial professionals in your country of residence to get personalized advice before you make any trading or investing decisions. This post was written with the assistance of artificial intelligence. The original ideas and final review are human-generated. Disclaimer